14:09 , Jun 3, 2019 |  BC Extra  |  Clinical News

Astellas, Seattle Genetics ADC could provide new option for checkpoint non-responders in bladder cancer

Data presented at ASCO on Monday for Astellas and Seattle Genetics' enfortumab vedotin showed that metastatic bladder cancer patients who don't respond or relapse after PD-1/PD-L1 therapy could soon have a new treatment option. In...
00:46 , May 11, 2019 |  BioCentury  |  Product Development

Now grown up, independent biotechs bulk up their platforms with more modalities

As the incoming class of independent biotechs look to build on their clinical and commercial successes, a handful are expanding beyond the technology that got them there, bringing in new modalities to complement their platforms...
16:22 , Mar 28, 2019 |  BC Extra  |  Clinical News

Seattle Genetics, Astellas ADC heading for bladder cancer submission

Seattle Genetics and Astellas plan to seek accelerated approval of antibody-drug conjugate enfortumab vedotin based on data from the pivotal Phase II EV-201 trial to treat bladder cancer. Interim results showed that among 128 patients...
03:20 , Feb 16, 2019 |  BioCentury  |  Product Development

ADCs’ inflection point

Industry is writing a new rule book for antibody-drug conjugates that could take the modality beyond the one-size-fits-all approach that has limited its success. By 2Q20, late-stage data from at least four ADCs testing new...
19:50 , Feb 15, 2019 |  BC Week In Review  |  Clinical News

Seattle Genetics gets $30M milestone for EU approval of Adcetris in first-line Hodgkin lymphoma

Seattle Genetics Inc. (NASDAQ:SGEN) will receive a $30 million milestone payment from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) triggered by the European Commission's decision to expand the label of Adcetris brentuximab vedotin to include previously untreated...
21:50 , Feb 8, 2019 |  BC Extra  |  Company News

Seattle Genetics down on light 2019 Adcetris sales guidance

Seattle Genetics Inc. (NASDAQ:SGEN) fell $8.73 (12%) to $65.02 Friday after announcing late Thursday 2019 guidance for Adcetris brentuximab vedotin sales below the consensus estimate. The move represents a market cap loss of almost $1.4...
00:23 , Jan 12, 2019 |  BioCentury  |  Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month’s gains and losing $291.2 billion in aggregate value. Median losses...
20:43 , Dec 21, 2018 |  BC Week In Review  |  Clinical News

CHMP backs Besremi for polycythemia vera, two Shionogi drugs

EMA's CHMP recommended a basket of approvals and label extensions on Dec. 14, including Orphan Drug Besremi ropeginterferon alfa-2b to treat polycythemia vera and a pair of treatments from Shionogi & Co. Ltd. (Tokyo:4507). The...
23:22 , Dec 14, 2018 |  BC Extra  |  Company News

CHMP backs Besremi for polycythemia vera, two Shionogi drugs

EMA's CHMP recommended a basket of approvals and label extensions on Friday, including Orphan Drug Besremi ropeginterferon alfa-2b to treat polycythemia vera and a pair of treatments from Shionogi & Co. Ltd. (Tokyo:4507). The agency...
21:06 , Dec 14, 2018 |  BC Week In Review  |  Clinical News

Adcetris improves PFS by 27.4 months in first-line PTCL

Seattle Genetics Inc. (NASDAQ:SGEN) and Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) reported detailed data from the Phase III ECHELON-2 trial to treat previously untreated CD30-expressing peripheral T cell lymphoma (PTCL) showing that Adcetris brentuximab vedotin plus...